Nevro Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nevro stock.
View analyst ratings for Nevro or view top-rated stocks.

Wall Street analysts have given Nevro a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nevro wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Nevro.

Nevro Corp. (NYSE:NVRO) announced its quarterly earnings data on Wednesday, May, 5th. The medical equipment provider reported ($0.85) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.86) by $0.01. The medical equipment provider earned $88.61 million during the quarter, compared to analyst estimates of $85.16 million. Nevro had a negative net margin of 24.16% and a negative trailing twelve-month return on equity of 23.26%.
View Nevro's earnings history.

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 62.0% and is now trading at $177.87.
View which stocks have been most impacted by COVID-19.

Nevro issued an update on its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $104 million-$106 million, compared to the consensus revenue estimate of $101.14 million.

11 brokers have issued twelve-month target prices for Nevro's stock. Their forecasts range from $160.00 to $225.00. On average, they expect Nevro's share price to reach $199.90 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price.
View analysts' price targets for Nevro or view top-rated stocks among Wall Street analysts.

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

Some companies that are related to Nevro include NovoCure (NVCR), Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), ShockWave Medical (SWAV), Tandem Diabetes Care (TNDM), Integra LifeSciences (IART), Inspire Medical Systems (INSP), Inari Medical (NARI), ICU Medical (ICUI), Glaukos (GKOS) and Cantel Medical (CMD).
View all of NVRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (13.50%), BlackRock Inc. (11.09%), Fred Alger Management LLC (6.29%), Jackson Square Partners LLC (3.41%), Franklin Resources Inc. (2.93%) and D. E. Shaw & Co. Inc. (2.19%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, D. E. Shaw & Co. Inc., Tiger Eye Capital LLC, Northern Trust Corp, Integral Health Asset Management LLC, Jackson Square Partners LLC, Russell Investments Group Ltd., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have sold Nevro company stock in the last year include Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro or view top insider-selling stocks.

NVRO stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Renaissance Technologies LLC, BlackRock Inc., Brown Advisory Inc., Great Point Partners LLC, Holocene Advisors LP, and Goldman Sachs Group Inc..
View insider buying and selling activity for Nevro or or view top insider-buying stocks.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVRO stock can currently be purchased for approximately $177.87.

Nevro has a market capitalization of $6.19 billion and generates $362.05 million in revenue each year. The medical equipment provider earns $-83,070,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

Nevro employs 843 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro is headquartered at 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]